On September 1, 2026, Rep. Nancy Mace introduced the PEPTIDES for Veterans Act, a bill that would order the Department of Veterans Affairs to study peptide-based therapies and, if the evidence holds up, offer them to veterans through a voluntary pilot program. It arrives five weeks after an FDA advisory committee voted to let compounding pharmacies make six peptides that are, as of today, still illegal to compound. This guide explains what the bill would actually do, what the science behind these compounds currently supports, and what a veteran can and cannot legally get right now.
What veterans need to know today
- The bill orders a study, not a prescription pad. Nothing in it makes any peptide available at the VA now. The first deliverable is a regulatory review report due 180 days after enactment, and the bill has not become law yet.
- The VA already uses peptides. Semaglutide, teriparatide and leuprolide are all peptide drugs the VA prescribes today. The bill is about the unapproved peptides, which is a much narrower question than the headlines suggest.
- The FDA has not signed off on anything. July’s advisory-committee vote was non-binding. BPC-157, TB-500, KPV, MOTS-c, epitalon and semax still cannot lawfully be compounded, and the FDA can still take enforcement action.
- Active duty is a completely different rulebook. BPC-157 sits on the DoD Prohibited Dietary Supplement Ingredients List under DoDI 6130.06. Separated veterans are not bound by it. Service members, including Guard and Reserve, are.
- The evidence is thinner than the marketing. BPC-157 has no completed randomized controlled trial in humans. Its first properly designed Phase 2 trial only began in February 2026 and does not report until 2027.
What the PEPTIDES for Veterans Act actually does
The full name is the Providing Evidence-based Peptide Therapies to Improve Delivery and Expanded Services for Veterans Act. Rep. Nancy Mace of South Carolina introduced it on September 1, 2026. At the time of writing, the bill number had not yet appeared in the public Congressional record; text and number typically post to congress.gov within a few days of introduction.
The mechanism is sequential, and each stage gates the next.
Two things are worth reading carefully. First, participation in any eventual pilot is voluntary by design, so this is not a plan to put peptides into standard VA care. Second, the pilot is conditional. It happens only if the 18-month study concludes that peptide-based therapies are safe and beneficial. A study that returns a null or mixed result ends the process there.
This structure mirrors how Congress has handled other contested treatments for veterans. Bipartisan legislation requiring the VA to study psychedelic treatments took the same study-first, pilot-second shape, as did the push to route veterans with TBI and PTSD toward hyperbaric oxygen therapy under H.R.72.
Why the bill is aimed at veterans specifically
The conditions the bill names, chronic pain, rehabilitation, mental health and recovery, map onto the conditions veterans carry at far higher rates than the general population.
- Roughly 28% of US veterans report chronic pain, against 19% of non-veterans. A systematic review covering more than 14 million veterans put it at about three in every ten.
- Among post-9/11 veterans who completed the VA’s Comprehensive TBI Evaluation, 59% with a history of mild TBI reported chronic pain. With comorbid PTSD that figure rises to 82%.
- Half of veterans with PTSD also report chronic pain. The conditions amplify each other rather than sitting side by side.
- Between 2001 and 2025, roughly 556,502 veterans screened positive for TBI or a TBI-related diagnosis in VA records, or filed a related disability claim.
- Among active-duty service members, 31% to 44% experience chronic pain, and musculoskeletal injury is the leading cause of limited-duty days and inability to deploy.
Against that, funding has moved the other way. Spending on TBI medical research fell from $175 million in fiscal 2024 to $40.5 million in fiscal 2026. That combination, a large population with poorly served conditions and a shrinking research budget, is the pressure the bill responds to, and it is also why an unregulated market has grown up around these compounds.
The VA already uses peptides. It just calls them drugs.
Coverage of this bill tends to imply the VA has no relationship with peptides. That is not accurate, and the distinction matters for understanding what would actually change.
A peptide is a short chain of amino acids. Plenty of them are ordinary FDA-approved medicines that the VA dispenses every day.
The VA is also actively researching peptides. In July 2026 it launched the CRAVE trial, short for Cessation or Reduction of Alcohol Consumption in Veterans, testing semaglutide against placebo in more than 600 veterans aged 18 to 80 with moderate or severe alcohol use disorder. Participants receive weekly injections for 24 weeks across 18 VA medical centers, with recruitment opening July 28, 2026 and results expected in spring 2027. Separately, a VA-funded project at the East Orange, New Jersey VA Medical Center has been studying an erythropoietin-derived peptide for neurodegeneration and neuroinflammation following repetitive mild TBI.
So the real question the PEPTIDES for Veterans Act poses is narrower than it looks: should the VA study the unapproved peptides, the ones sold today as research chemicals, alongside the approved ones it already prescribes?
The six peptides an FDA panel backed in July
On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted on seven peptides for the 503A Bulks List, the roster of substances compounding pharmacies may legally prepare. Six passed. We covered the votes in detail in our FDA peptide vote 2026 breakdown.
The critical caveat: an advisory committee vote is not an agency action. The recommendations are non-binding, the FDA has not issued a final decision, and until it does, none of these peptides may lawfully be compounded. The agency can still take enforcement action against pharmacies that make them. A second PCAC meeting covering five additional peptides is expected in February 2027.
What the evidence actually shows
If the VA runs the study this bill orders, this is the literature it will be reviewing. It is worth being blunt about its state.
BPC-157
BPC-157 is the compound most veterans ask about, usually for tendon, ligament or back injuries. Its preclinical record is genuinely large, with more than 200 peer-reviewed animal studies over three decades and no major safety signal so far. Its human record is not. As of 2026 there is no completed, peer-reviewed Phase I to III trial published in a major journal, no approved formulation and no validated dosing regimen. The published human evidence amounts to three studies with fewer than 30 subjects between them, none of them randomized controlled trials.
That is beginning to change. The first properly designed Phase 2 trial, NCT07437547, run by Hudson Biotech in acute hamstring strain, began on February 2, 2026 and has an estimated primary completion date of February 14, 2027. Anyone claiming BPC-157 is proven in humans is describing a trial that has not reported yet. Our BPC-157 research guide and the deeper look at BPC-157 for tendon, back and nerve injuries go through the preclinical work in detail.
Semax
Semax has the strongest human record of the six, which says as much about the others as it does about semax. It is an ACTH(4-7)-derived heptapeptide registered with the Russian Ministry of Health in 1994 for cerebrovascular indications, and it holds Russian approval for acute ischemic stroke and traumatic brain injury among other uses. The best-known trial followed 110 post-stroke patients on 6,000 mcg per day intranasally and reported improvements on the Barthel index and MRC motor scale.
The limitation is structural: that trial was neither randomized nor placebo-controlled, and it came from a single research group. No large Western multicentre randomized trial has confirmed the findings. For a veteran with a TBI history this is the most interesting compound on the list and the one with the least Western validation. See our semax guide for the full picture.
TB-500, KPV, MOTS-c and epitalon
TB-500, a synthetic fragment related to thymosin beta-4, is studied for muscle and connective-tissue repair and rests almost entirely on preclinical work. KPV, a tripeptide fragment of alpha-MSH, has anti-inflammatory data in animal and cell models and very little in humans. MOTS-c is a mitochondrial-derived peptide under evaluation for obesity and osteoporosis, with no completed human efficacy trial. Epitalon rests on small Russian studies of sleep and circadian markers that Western groups have largely not replicated.
None of these is fraudulent and none is proven. They sit in the same category: mechanistically interesting, commercially popular, and thin on the controlled human trials that would let the VA prescribe them with confidence.
What a veteran can legally access today
Nothing about the bill or the July vote has changed the legal position. As things stand:
- The VA will not prescribe BPC-157, TB-500, KPV, MOTS-c, epitalon or semax. There is no VA policy authorizing them, and they are unapproved drugs.
- Compounding pharmacies cannot lawfully make them either. The PCAC recommendation has no legal force until the FDA acts on it.
- The material sold online is sold as a research chemical. Labels reading “research use only” or “not for human consumption” do not change what the compound is; the FDA treats these as unapproved drugs regardless of how they are labeled.
- Approved peptide drugs remain available normally through VA care where clinically indicated, which is the route worth exhausting first.
- Clinical trials are a real option. Trials such as NCT07437547 and the VA’s own CRAVE study are the only settings where these compounds are administered under monitoring, at a known dose and at no cost to the participant.
If you want the full breakdown of routes and their legal standing, our guide on how to get BPC-157 in 2026 walks through each one.
Active duty, Guard and Reserve: a different rulebook
This is the distinction most coverage misses, and it has career consequences.
BPC-157 appears on the DoD Prohibited Dietary Supplement Ingredients List, and the Department of Defense prohibits its use by service members under DoDI 6130.06. The Department’s Operation Supplement Safety program tells service members to avoid research chemicals and any product containing a prohibited ingredient, in any form: oral, injectable or nasal spray. Prohibition applies on a strict-liability basis, meaning intent and ignorance of a product’s contents are not defenses.
The practical split:
- Currently serving, including Guard and Reserve: prohibited compounds carry real risk to your career, independent of anything Congress or the FDA decides about civilian access.
- Separated veterans: DoD supplement policy no longer applies to you. The remaining constraints are federal drug law, which makes these unapproved drugs, and your own risk tolerance.
A bill that expands what the VA may study does not change DoD policy for people still in uniform. Those are two different agencies operating under two different authorities.
Does using peptides affect VA health care or disability claims?
VA health care eligibility and disability compensation are determined by service connection and by the severity of the rated condition. They are not conditioned on avoiding non-VA treatments, and there is no rule stripping benefits from a veteran who uses an unapproved compound.
The practical risks lie elsewhere. Undisclosed use can interfere with VA care in ways that matter: unexplained lab results, interactions with prescribed medication, and a clinical picture your VA provider is trying to interpret without a key piece of information. If you are using anything, tell your VA provider. Clinicians document what you report so they can treat you safely, and that conversation is a normal part of care rather than an enforcement mechanism.
What to do while the bill moves
- Exhaust the approved routes first. For chronic pain, TBI and PTSD, the VA has treatments with real evidence behind them. An unapproved peptide is not a substitute for a care plan that has not been tried yet.
- Ask about clinical trials. Trial participation is the only monitored, no-cost way to access these compounds, and VA research staff can point you at what is recruiting.
- Treat marketing claims as marketing. Any vendor telling you a peptide is clinically proven for TBI, PTSD or chronic pain is ahead of the evidence, in some cases by years.
- If you are still serving, stop at the prohibited list. Check Operation Supplement Safety before anything else.
- Watch two dates. The FDA’s final decision on the July recommendations, and the February 2027 PCAC meeting on five more peptides.
What happens next
The bill has been introduced, which is the beginning of the process rather than the end of it. It goes to committee, and most introduced bills do not become law. Even on the fastest realistic path, the sequence runs: passage, then 180 days to the regulatory review, then an 18-month study, then a pilot. A veteran reading this in September 2026 should expect the earliest meaningful VA pilot to be years away, not months.
The FDA’s decision on the PCAC recommendations is the nearer-term event, because it determines whether a legal compounding route exists at all. Without one, any VA pilot would face an awkward supply question: where would the peptides come from?
Frequently Asked Questions
Sources
- Rep. Nancy Mace Introduces Bill To Expand Access To Cutting-Edge Peptide Therapies. Office of Rep. Nancy Mace, September 1, 2026.
- FDA’s Advisory Committee Votes on Peptides: What It Does and Does Not Mean. Mintz, July 29, 2026.
- FDA Panel Backs 6 Peptides for Compounding. The American Journal of Managed Care, 2026.
- BPC 157 for Acute Hamstring Muscle Strain Repair (NCT07437547). ClinicalTrials.gov.
- VA launches trial of GLP-1 treatment for alcohol use disorder. US Department of Veterans Affairs, July 2026.
- Novel EPO peptide therapy for chronic rmTBI dependent neurodegeneration and neuroinflammation. VA Office of Research and Development, FY2024.
- Chronic Pain in Veterans and Servicemembers with a History of Mild Traumatic Brain Injury. VA Evidence Synthesis Program.
- PTSD and Chronic Pain. National Center for PTSD, PTSD Research Quarterly.
- BPC-157: A Prohibited Peptide and an Unapproved Drug Found in Health and Wellness Products. Operation Supplement Safety, Department of Defense.
- H.R.72 – TBI and PTSD Treatment Act. 119th Congress.
- House-Passed Bill Reauthorizes These Three Traumatic Brain Injury Programs. Military.com, 2026.
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide: Literature and Patent Review. Pharmaceuticals, 2025.
The information in this article is for educational purposes only and does not constitute medical advice. BPC-157, TB-500, KPV, MOTS-c, epitalon and semax are not approved by the FDA for the treatment of any condition, and no peptide discussed here is an established treatment for TBI, PTSD or chronic pain. Veterans should discuss any treatment decision with a VA clinician or another qualified healthcare professional. Currently serving members should consult Operation Supplement Safety before using any supplement or compound.
